Drugs / VIPALANEBART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03692949 | Dec 2018 → Feb 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04498910 | Nov 2020 → Nov 2022 | migraine disorder | Eli Lilly and Company | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIPALANEBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314614 ↗ |
| Known as | LY3451838 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04498910 ↗ |
| Action | Inhibit | “LY3451838, a PACAP-neutralizing monoclonal antibody” PMID 40836866 ↗ Aug 2025 |
| Modality | Monoclonal antibody | “LY3451838, a PACAP-neutralizing monoclonal antibody” PMID 40836866 ↗ Aug 2025 |
| Route | Intravenous | “single increasing doses of LY3451838 will be administered intravenously (into a vein).” NCT03692949 ↗ |